News | Artificial Intelligence | July 03, 2019

Therapixel Appoints Matthieu Leclerc-Chalvet as CEO

Company now shifts focus to launch of breast cancer screening artificial intelligence solution

Therapixel Appoints Matthieu Leclerc-Chalvet as CEO

July 3, 2019 — Artificial intelligence (AI) breast cancer screening specialist Therapixel announced the appointment of Matthieu Leclerc-Chalvet as chief executive officer on June 14, 2019. This follows a 5 million euros series A fundraising, and the appointment of Sacha Loiseau as chairman of the board. Leclerc-Chalvet is also joining the board of directors.

Leclerc-Chalvet brings 30 years of experience in the development and commercialization of medical devices. After 20 years abroad, working for multinational organizations as well as start-ups, he chose to return to France to share his experience with Therapixel. Until now, Leclerc-Chalvet was managing director of Mirada Medical, a British company specialized in medical imaging software, where he orchestrated a pivot towards AI, leading to the launch of the first AI software in radiotherapy.

Leclerc-Chalvet declared, “I am thrilled to join a team of such technical and scientific excellence, and to bring my strategic and operational expertise in adoption of medical technology innovation globally.” 

This appointment allows Therapixel co-founder and interim CEO Pierre Fillard to focus on his role of chief scientific officer (CSO). He will work alongside Leclerc-Chalvet on completing the AI breast cancer screening product and going through the regulatory approvals leading to the commercial launch.

Read the article "Therapixel Wins the Digital Mammography Challenge"

For more information: www.therapixel.com

Related Content

Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
New Lung Ambition Alliance Aims to Double Five-year Lung Cancer Survival by 2025
News | Lung Cancer | July 17, 2019
The International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (...
Graphic courtesy Pixabay

Graphic courtesy Pixabay

Feature | Artificial Intelligence | July 15, 2019 | By Greg Freiherr
Siemens has long focused on automation as a way to make diagnostic equipment faster and more efficient.
Videos | Artificial Intelligence | July 12, 2019
Khan Siddiqui, M.D., founder and CEO of HOPPR, discusses the economic advantages and costs presented by...
Videos | Digital Pathology | July 11, 2019
Toby Cornish, M.D., Ph.D., associate professor and medical director of informatics at the University of Colorado Scho
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...
Infervision Releases InferTEST Program at SIIM 2019
News | Artificial Intelligence | July 08, 2019
Infervision announced their InferTEST program at the recent Society for Imaging Informatics in Medicine (SIIM)...